The “Immuno-Oncology – Market Analysis, Trends, Opportunities and Unmet Needs – Thematic Research” report has been added to ResearchAndMarkets.com’s offering.
Immuno-Oncology report provides the landscape of marketed and pipeline immuno-oncology drugs across the five major classes (bispecific antibodies, cancer vaccines, cell therapies, checkpoint modulators and oncolytic viruses), opportunities, challenges, and unmet needs.
Immuno-oncology (IO) describes the treatment of various cancers with the use of bispecific-antibodies, cancer vaccines, cell therapies, checkpoint modulators and oncolytic viruses. These classes of IO therapies achieved sales of ~$30B in 2019, which is projected to reach ~$95B by 2026. Of these, checkpoint modulators is the most valuable segment, forecast to achieve $66B in sales by 2026.
The field of (IO) is consolidating its presence in most major types of cancer, as there are now 22 marketed agents in the 7MM (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), the majority being cancer vaccines, followed by 8 checkpoint modulators and 4 cell therapies.
IO agents are part of the standard of care in major cancer types, such as Melanoma, Lung, and Head & Neck Cancer. The clinical activity in the field is among the highest in oncology, with 4,822 clinical trials in the 7MM as of December 2020 and 422 drugs in clinical development.
Key findings from the report include
- The field of immuno-oncology (IO) is consolidating its presence in most major types of cancer: There are currently 22 marketed IO products in the 7MM. Prophylactic and therapeutic cancer vaccines lead the category with 9 products, followed by checkpoint modulators with 8 approved drugs and cell therapies with 4 approved drugs. As of December 2020, there are 4,822 clinical trials investigating IO across the 7MM with 422 drugs in development.
- Checkpoint modulation is the most valuable IO sector: The checkpoint modulation market was valued at $24B in 2019 globally and is forecast to reach $66.5B by 2026, with Merck’s Keytruda (pembrolizumab) leading the market. Key patent expiries for checkpoint modulators in the decade 2020-2030 will start eroding market value away from branded agents and into biosimilars.
- Existing programs facilitate the approval and development of IO: Special new designations for certain components of IO can be assigned such as RMAT in the US and ATMP in the EU. Countries in the 7MM have set programs to expedite IO therapy approvals, especially when they address an unmet need or are targeting orphan indications.
- High cost of therapy and need for personalized treatment using biomarkers remain as unmet needs: Despite new competitors entering the market, IO agents have retained or increased their very high prices, causing concern for their future use in most markets The need for better biomarkers to guide treatment decisions is well-documented and new efforts in the industry may move the needle in the next five years.
- Robust analysis of high-prescriber survey conducted with 80 oncologists.
Key Topics Covered:
2. Executive Summary
3. Immuno-oncology Overview
3.1. What is Immuno-oncology?
3.2. Most Important Milestones of Immuno-oncology Development Globally
3.3. Key Twitter Chat
4.1. Industry Trends – Bispecific Antibodies
4.2. Industry Trends – Cancer Vaccines
4.3. Industry Trends – Cell Therapies
4.4. Industry Trends – Checkpoint Modulators
4.5. Industry Trends – Oncolytic Viruses
4.6. Regulatory Trends
5. Value Chain
5.1. Immuno-oncology Value Chain
5.2. Bispecific Antibodies
5.3. Cancer Vaccines
5.4. Cell Therapies
5.5. Checkpoint Modulators
5.6. Oncolytic Viruses
5.7. Immuno-oncology in Clinical Trials
6. Marketed Products
6.1. Marketed Immuno-oncology Products in the 7MM
6.2. Total Market Size for Immuno-oncology Agents
6.3. Ten Highest-grossing Immuno-oncology Treatments in 2019
6.4. Leading Checkpoint Modulators in The 7MM
6.5. Leading Cancer Vaccines, Bispecific Antibodies and Oncolytic Viruses in The 7MM
6.6. Leading Cell Therapies in The 7MM
7. Pipeline Products
7.1. Immuno-oncology Pipeline Products in the 7MM
7.2. Pipeline Products by Type and Phase
7.3. Future Outlook of Immuno-oncology Agents According to High-Prescribing Physicians
7.4. Consensus Forecast Sales for the Top Products per Class of Immuno-oncology
7.5. Late Stage Bispecific Antibody Products
7.6. Late Stage Cancer Vaccine Products
7.7. Late Stage Cell Therapy Products
7.8. Late Stage Checkpoint Modulator Products
7.9. Late Stage Oncolytic Virus Products
8. Market Analysis and Deals
8.1. Immuno-oncology Market Analysis and Forecast by Class of Therapy
8.2. Top 10 Transaction Deals by Size during 2011-2020 in the Immuno-oncology Space
8.3. Latest Transaction Deals in the Immuno-oncology Space
8.4. Mergers and Acquisitions That Include Immuno-oncology Assets: 2019 – 2020
8.5. Mergers and Acquisitions That Include Immuno-oncology Assets: 2014 – 2018
9. Regulatory and Market Access
9.1. Immuno-oncology in Clinical Trials
9.2. Differences in Immuno-oncology Clinical Trials – KOLs Perspective
9.3. Challenges in Immuno-oncology Clinical Trials – KOLs Perspective
9.4. Regulatory and Market Access – US
9.5. Regulatory and Market Access – Europe
9.6. Regulatory and Market Access – Japan
9.7. Comparison of Early Access Schemes in the US, EU, and Japan
9.8. Barriers to Access According to High Prescribers
10. Opportunities, Challenges, and Unmet Needs
10.1. Bispecific Antibodies – Opportunities & Challenges
10.2. Cancer Vaccines – Opportunities & Challenges
10.3. Cell Therapies- Opportunities & Challenges
10.4. Checkpoint Modulators – Opportunities & Challenges
10.5. Oncolytic Viruses – Opportunities & Challenges
10.6. Clinical Unmet Needs in Immuno-oncology – Gap Analysis
10.7. Commercial Unmet Needs in Immuno-oncology – Gap Analysis
10.8. Unmet Needs – KOLs Perspective
10.9. Unmet Needs According to High Prescribers
10.10. R&D Strategies
10.11. Opportunities According to KOLs and Closing Remarks
11.1. Drug Development Scorecard
11.1.1. Current Major Players
11.1.3. Merck & Co
11.1.6. Bristol-Myers Squibb
11.2. Future Players Based on Pipeline Strength
11.2.2. Bluebird Bio
11.2.4. Iovance Biotherapeutics
11.2.7. SELLAS Life Sciences
For more information about this report visit https://www.researchandmarkets.com/r/mduvqu
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900